Topographical Distribution of Aβ Predicts Progression to Dementia in Aβ Positive Mild Cognitive Impairment

Overview

Journal Alzheimers Dement (Amst)

Date 2020 Jun 26

PMID 32582834

Citations 10

Authors

Tharick A Pascoal

Joseph Therriault

Sulantha Mathotaarachchi

Min Su Kang

Monica Shin

Andrea L Benedet

Mira Chamoun

Cecile Tissot

Firoza Lussier

Sara Mohaddes

Jean-Paul Soucy

Gassan Massarweh

Serge Gauthier

Pedro Rosa-Neto

Affiliations

Soon will be listed here.

Abstract

Introduction: Abnormal brain amyloid beta (Aβ) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown whether the assessment of the topographical distribution of Aβ pathology can provide additional information to identify, among global Aβ positive individuals, those destined for dementia.

Methods: We studied 260 amnestic mild cognitive impairment (MCI) subjects who were Aβ-PET positive with [F]florbetapir. Using [F]florbetapir, we assessed the percentage of voxels sowing Aβ abnormality as well as the standardized uptake value ratio (SUVR) values across brain regions. Regressions tested the predictive effect of Aβ on progression to dementia over 2 years.

Results: Neither global nor regional [F]florbetapir SUVR concentrations predicted progression to dementia. In contrast, the spatial extent of Aβ pathology in regions comprising the default mode network was highly associated with the development of dementia over 2 years.

Discussion: These results highlight that the regional distribution of Aβ abnormality may provide important complementary information at an individual level regarding the likelihood of Aβ positive MCI to progress to dementia.

Citing Articles

Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer's disease biomarkers.

Ivarsson Orrelid C, Rosberg O, Weiner S, Johansson F, Gobom J, Zetterberg H Fluids Barriers CNS. 2025; 22(1):23.

PMID: 40033432 PMC: 11874791. DOI: 10.1186/s12987-025-00634-z.

Mapping amyloid beta predictors of entorhinal tau in preclinical Alzheimer's disease.

Zamani J, Vahid A, Avelar-Pereira B, Gozdas E, Hosseini S Alzheimers Dement. 2025; 21(2):e14499.

PMID: 39777850 PMC: 11848422. DOI: 10.1002/alz.14499.

Evaluation of ComBat Harmonization for Reducing Across-Tracer Differences in Regional Amyloid PET Analyses.

Yang B, Earnest T, Kumar S, Kothapalli D, Benzinger T, Gordon B Hum Brain Mapp. 2024; 45(16):e70068.

PMID: 39540665 PMC: 11561838. DOI: 10.1002/hbm.70068.

Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET.

Therriault J, Lussier F, Tissot C, Chamoun M, Stevenson J, Rahmouni N Alzheimers Dement (Amst). 2023; 15(3):e12391.

PMID: 37644990 PMC: 10461075. DOI: 10.1002/dad2.12391.

Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.

Jovalekic A, Roe-Vellve N, Koglin N, Quintana M, Nelson A, Diemling M Eur J Nucl Med Mol Imaging. 2023; 50(11):3276-3289.

PMID: 37300571 PMC: 10542295. DOI: 10.1007/s00259-023-06279-0.

References

Rabinovici G, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L . Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019; 321(13):1286-1294. PMC: 6450276. DOI: 10.1001/jama.2019.2000. View

Altmann A, Ng B, Landau S, Jagust W, Greicius M . Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain. 2015; 138(Pt 12):3734-46. PMC: 4806718. DOI: 10.1093/brain/awv278. View

Buckner R, Snyder A, Shannon B, LaRossa G, Sachs R, Fotenos A . Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005; 25(34):7709-17. PMC: 6725245. DOI: 10.1523/JNEUROSCI.2177-05.2005. View

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

Walsh D, Selkoe D . A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci. 2016; 17(4):251-60. PMC: 6701169. DOI: 10.1038/nrn.2016.13. View

Sakr F, Grothe M, Cavedo E, Jelistratova I, Habert M, Dyrba M . Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimers Res Ther. 2019; 11(1):15. PMC: 6357385. DOI: 10.1186/s13195-019-0466-3. View

Mathotaarachchi S, Wang S, Shin M, Pascoal T, Benedet A, Kang M . VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. Front Neuroinform. 2016; 10:20. PMC: 4908129. DOI: 10.3389/fninf.2016.00020. View

Pascoal T, Therriault J, Mathotaarachchi S, Kang M, Shin M, Benedet A . Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment. Alzheimers Dement (Amst). 2020; 12(1):e12037. PMC: 7306519. DOI: 10.1002/dad2.12037. View

Klein A, Tourville J . 101 labeled brain images and a consistent human cortical labeling protocol. Front Neurosci. 2012; 6:171. PMC: 3514540. DOI: 10.3389/fnins.2012.00171. View

10.

Laforce Jr R, Rabinovici G . Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther. 2011; 3(6):31. PMC: 3308020. DOI: 10.1186/alzrt93. View

11.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

12.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski J, Bittner T . CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018; 14(11):1470-1481. PMC: 6119541. DOI: 10.1016/j.jalz.2018.01.010. View

13.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

14.

Buckley R, Mormino E, Amariglio R, Properzi M, Rabin J, Lim Y . Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018; 14(9):1193-1203. PMC: 6131023. DOI: 10.1016/j.jalz.2018.04.010. View

15.

Mattsson N, Groot C, Jansen W, Landau S, Villemagne V, Engelborghs S . Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimers Dement. 2018; 14(7):913-924. DOI: 10.1016/j.jalz.2018.02.009. View

16.

Zijdenbos A, Forghani R, Evans A . Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging. 2003; 21(10):1280-91. DOI: 10.1109/TMI.2002.806283. View

17.

Eskildsen S, Coupe P, Fonov V, Manjon J, Leung K, Guizard N . BEaST: brain extraction based on nonlocal segmentation technique. Neuroimage. 2011; 59(3):2362-73. DOI: 10.1016/j.neuroimage.2011.09.012. View

18.

Villeneuve S, Rabinovici G, Cohn-Sheehy B, Madison C, Ayakta N, Ghosh P . Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015; 138(Pt 7):2020-33. PMC: 4806716. DOI: 10.1093/brain/awv112. View

19.

Schreiber S, Landau S, Fero A, Schreiber F, Jagust W . Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. JAMA Neurol. 2015; 72(10):1183-90. DOI: 10.1001/jamaneurol.2015.1633. View

20.

Ikonomovic M, Klunk W, Abrahamson E, Mathis C, Price J, Tsopelas N . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008; 131(Pt 6):1630-45. PMC: 2408940. DOI: 10.1093/brain/awn016. View